{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:10:58Z","timestamp":1790997058872,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.resinv.2026.101453","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:39:07Z","timestamp":1779701947000},"page":"101453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early risk response to vasodilators and outcomes in interstitial lung disease associated pulmonary hypertension"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9764-0126","authenticated-orcid":false,"given":"Ryo","family":"Teramachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Fukihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reoto","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-3329","authenticated-orcid":false,"given":"Tomoki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101453_bib1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101453_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12931-021-01749-1","article-title":"Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)","volume":"22","author":"Nasser","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2026.101453_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101453_bib4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.chest.2020.02.043","article-title":"Pulmonary vascular and right ventricular burden during exercise in interstitial lung disease","volume":"158","author":"Oliveira","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101453_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/thorax-2023-220179","article-title":"Mild elevation of pulmonary vascular resistance predicts mortality regardless of mean pulmonary artery pressure in mild interstitial lung disease","volume":"79","author":"Sato","year":"2024","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2026.101453_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101453_bib7","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/resp.12294","article-title":"Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors","volume":"19","author":"Zimmermann","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2026.101453_bib8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.rmed.2008.02.002","article-title":"Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease","volume":"102","author":"Minai","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2026.101453_bib9","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.chest.2020.04.046","article-title":"The trouble with group 3 pulmonary hypertension in interstitial lung disease: dilemmas in diagnosis and the conundrum of treatment","volume":"158","author":"King","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101453_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101453_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02311-2021","article-title":"Compera 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension","volume":"60","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101453_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02419-2021","article-title":"External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry","volume":"59","author":"Boucly","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101453_bib13","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101453_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.13-1474","article-title":"Predicting survival across chronic interstitial lung disease: the ILD-GAP model","volume":"145","author":"Ryerson","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101453_bib15","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.revmed.2019.04.003","article-title":"Benefits and risks of oxygen therapy during acute medical illness: just a matter of dose!","volume":"40","author":"Allardet-Servent","year":"2019","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.resinv.2026.101453_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4037\/ccn2002.22.4.41","article-title":"Using a reservoir nasal cannula in acute care","volume":"22","author":"Dumont","year":"2002","journal-title":"Crit Care Nurse"},{"key":"10.1016\/j.resinv.2026.101453_bib17","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101453_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS committee on proficiency standards for clinical pulmonary function laboratories. ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101453_bib19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.resinv.2026.101453_bib20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2026.101453_bib21","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.3390\/jcm9123828","article-title":"Predictors of mortality in patients with interstitial lung disease-associated pulmonary hypertension","volume":"9","author":"Alhamad","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2026.101453_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011464","article-title":"Clinical determinants and prognostic implications of right ventricular dysfunction in pulmonary hypertension caused by chronic lung disease","volume":"8","author":"Prins","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.resinv.2026.101453_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101453_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.chest.2024.03.018","article-title":"Comparison of contemporary risk scores in all groups of pulmonary hypertension: a pulmonary vascular research institute GoDeep meta-registry analysis","volume":"166","author":"Yogeswaran","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101453_bib25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41512","volume":"73","author":"Chauvelot","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2026.101453_bib26","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1164\/rccm.202412-2371OC","article-title":"Hemodynamics and phosphodiesterase-5 inhibitor treatment associated with survival in pulmonary hypertension in interstitial lung disease: a PVRI GoDeep meta-registry analysis","volume":"211","author":"Yogeswaran","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101453_bib27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacasi.2024.01.009","article-title":"Pulmonary hypertension with interstitial pneumonia: initial treatment effectiveness and severity in a Japan registry","volume":"4","author":"Tanabe","year":"2024","journal-title":"JACC Asia"},{"key":"10.1016\/j.resinv.2026.101453_bib28","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1378\/chest.06-2101","article-title":"Sildenafil improves walk distance in idiopathic pulmonary fibrosis","volume":"131","author":"Collard","year":"2007","journal-title":"Chest"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:39:36Z","timestamp":1784029176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2212534526000870"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101453","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early risk response to vasodilators and outcomes in interstitial lung disease associated pulmonary hypertension","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101453"}}